Willow Biosciences Inc (ATLE) AI Stock Analysis

• Market Cap: C$65.16M
• Dividend Yield: N/A
• Average Volume (3M): 45.61K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.50
• Revenue Growth: 571.23%
• EPS Growth: 64.25%
• Country: CA
• Employees: 19
• Sector: Healthcare
• Sector Strength: 49
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 352,222,660
• 10 Day Avg. Volume: 33,939
• 30 Day Avg. Volume: 45,611
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 44 Neutral
• Price Target: C$0.00 ▼(-100.00% Downside)

The overall stock score reflects significant financial challenges, including negative equity and cash flow issues, which are the most impactful factors. Despite strong revenue growth, the financial instability and negative valuation metrics weigh heavily on the score. Technical indicators suggest a bearish trend, further influencing the overall score.

Willow Biosciences Inc Business Overview & Revenue Model

Company Description

Willow Biosciences Inc. is a biotechnology company dedicated to the research, development, and production of high-purity, plant-derived ingredients for the pharmaceutical, health and wellness, and consumer packaged goods industries. The company leverages its proprietary biosynthetic technology platform to produce bio-based chemicals that offer a sustainable alternative to traditional chemical synthesis methods.

How the Company Makes Money

Willow Biosciences Inc. generates revenue through the production and sale of its biosynthetically produced ingredients, which are used in various sectors such as pharmaceuticals, health and wellness, and consumer products. The company partners with industry players to integrate its high-purity ingredients into their product lines, providing a sustainable and cost-effective alternative to traditional products. Additionally, revenue is also driven by strategic collaborations and partnerships that help expand the application and reach of its biosynthetic technology. By focusing on high-value, plant-derived chemicals, Willow Biosciences capitalizes on the growing demand for sustainable and naturally sourced ingredients.

Willow Biosciences Inc Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Willow Biosciences Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.18
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ATLE, the sentiment is Negative. The current price of 0.18 is below the 20-day moving average (MA) of 0.19, below the 50-day MA of 0.20, and below the 200-day MA of 0.26, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.11 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ATLE.

Willow Biosciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	47 Neutral	C$212.91M	-1.44	-30.33%	3.10%	19.48%	-0.04%
ATLE	44 Neutral	C$65.16M	―	-971.43%	―	571.23%	64.25%
OVAT	39 Underperform	$1.76M	―	62.01%	―	46.42%	54.75%
CVGR	20 Underperform	$2.28M	―	49.80%	―	-100.00%	69.16%

Willow Biosciences Inc Corporate Events

Atlas Energy Corp. Appoints Andy Duncan to Bolster Leadership Team

Atlas Energy Corp. has appointed Andy Duncan as a Senior Executive, bringing over 34 years of experience in the oil and gas sector and energy finance. This strategic appointment is expected to enhance Atlas’s global growth ambitions, leveraging Duncan’s extensive expertise in building strategic partnerships and navigating complex regulatory environments.